182 related articles for article (PubMed ID: 22555371)
1. Treatment of 5/6 nephrectomy rats with sulodexide: a novel therapy for chronic renal failure.
Li P; Ma LL; Xie RJ; Xie YS; Wei RB; Yin M; Wang JZ; Chen XM
Acta Pharmacol Sin; 2012 May; 33(5):644-51. PubMed ID: 22555371
[TBL] [Abstract][Full Text] [Related]
2. Sulodexide ameliorates early but not late kidney disease in models of radiation nephropathy and diabetic nephropathy.
Rossini M; Naito T; Yang H; Freeman M; Donnert E; Ma LJ; Dunn SR; Sharma K; Fogo AB
Nephrol Dial Transplant; 2010 Jun; 25(6):1803-10. PubMed ID: 20061322
[TBL] [Abstract][Full Text] [Related]
3. [Effects of combination therapy with angiotensin I-converting enzyme inhibitor and angiotensin 1 receptor antagonist on ventricular remodeling and expression of endothelial nitric oxide synthase].
Zhang RY; Huang YL; Sun YH
Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(15):1053-6. PubMed ID: 16029550
[TBL] [Abstract][Full Text] [Related]
4. Effects and mechanism of irbesartan on tubulointerstitial fibrosis in 5/6 nephrectomized rats.
Zhao G; Zhao H; Tu L; Xu X; Zheng C; Jiang M; Wang P; Wang D
J Huazhong Univ Sci Technolog Med Sci; 2010 Feb; 30(1):48-54. PubMed ID: 20155455
[TBL] [Abstract][Full Text] [Related]
5. [Effects of irbesartan on nitric oxide system in the heart of diabetic rats].
Qian XX; Chen YM; Wu WK; Liu Y; Zhou B; Liu JL; Chen L
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Sep; 26(9):1359-62. PubMed ID: 16982456
[TBL] [Abstract][Full Text] [Related]
6. [Renal protective effect of angiotensin II receptor antagonist on growth hormone-treated nephrotic rats].
Li S; Cao B; Feng QH; Li XZ
Zhonghua Er Ke Za Zhi; 2003 Nov; 41(11):817-21. PubMed ID: 14728886
[TBL] [Abstract][Full Text] [Related]
7. Anti-inflammatory renoprotective effect of clopidogrel and irbesartan in chronic renal injury.
Tu X; Chen X; Xie Y; Shi S; Wang J; Chen Y; Li J
J Am Soc Nephrol; 2008 Jan; 19(1):77-83. PubMed ID: 18045851
[TBL] [Abstract][Full Text] [Related]
8. Effect of irbesartan on the antioxidant defence system and nitric oxide release in diabetic rat kidney.
Anjaneyulu M; Chopra K
Am J Nephrol; 2004; 24(5):488-96. PubMed ID: 15353911
[TBL] [Abstract][Full Text] [Related]
9. Influence of irbesartan on expression of ILK and its relationship with epithelial-mesenchymal transition in mice with unilateral ureteral obstruction.
Liu BC; Xia HL; Wu JN; Zhang XL; Liu DG; Gong YX
Acta Pharmacol Sin; 2007 Nov; 28(11):1810-8. PubMed ID: 17959033
[TBL] [Abstract][Full Text] [Related]
10. [Slowing the progression of chronic renal insufficiency with captopril in rats with spontaneous arterial hypertension and adriamycin nephropathy].
Jovanović DB; Jovović Dj; Varagić J; Dimitrijević J; Dragojlović Z; Djukanović L
Srp Arh Celok Lek; 2002; 130(3-4):73-80. PubMed ID: 12154518
[TBL] [Abstract][Full Text] [Related]
11. Treatment with irbesatan may improve slit diaphragm alterations in rats with adriamycin-induced nephropathy.
Wang N; Wei RB; Li P; Li QP; Yang X; Yang Y; Huang MJ; Wang R; Yin Z; Lv Y; Chen XM
J Renin Angiotensin Aldosterone Syst; 2016; 17(2):1470320316646884. PubMed ID: 27169889
[TBL] [Abstract][Full Text] [Related]
12. Combined effects of irbesartan and carvedilol on expression of tissue factor and tissue factor pathway inhibitor in rats after myocardial infarction.
Yu J; Zhao J; Liu W; Ge Z; Du Y
Heart Vessels; 2011 Nov; 26(6):646-53. PubMed ID: 21229253
[TBL] [Abstract][Full Text] [Related]
13. Irbesartan ameliorates diabetic nephropathy by reducing the expression of connective tissue growth factor and alpha-smooth-muscle actin in the tubulointerstitium of diabetic rats.
Ren X; Guan G; Liu G; Liu G
Pharmacology; 2009; 83(2):80-7. PubMed ID: 19065061
[TBL] [Abstract][Full Text] [Related]
14. Additive renoprotective effect of candesartan and tetrahydrobiopterin in rats after 5/6 nephrectomy.
Podjarny E; Bernheim J; Hasdan G; Karsh D; Rashid G; Green J; Katz B; Bernheim J
Nephrol Dial Transplant; 2007 Jul; 22(7):1864-72. PubMed ID: 17442743
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis.
Naito T; Ma LJ; Yang H; Zuo Y; Tang Y; Han JY; Kon V; Fogo AB
Am J Physiol Renal Physiol; 2010 Mar; 298(3):F683-91. PubMed ID: 20042458
[TBL] [Abstract][Full Text] [Related]
16. Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with irbesartan in a rat model of diabetic nephropathy.
Abdel-Wahab AF; Bamagous GA; Al-Harizy RM; ElSawy NA; Shahzad N; Ibrahim IA; Ghamdi SSA
Biomed Pharmacother; 2018 Jul; 103():59-66. PubMed ID: 29635129
[TBL] [Abstract][Full Text] [Related]
17. The angiotensin receptor antagonist, irbesartan, reduces renal injury in experimental chronic renal failure.
Ziai F; Ots M; Provoost AP; Troy JL; Rennke HG; Brenner BM; Mackenzie HS
Kidney Int Suppl; 1996 Dec; 57():S132-6. PubMed ID: 8941934
[TBL] [Abstract][Full Text] [Related]
18. Increased osteopontin expression following renal ablation is attenuated by angiotensin type 1 receptor antagonism.
Cao Z; Cox A; Bonnet F
Exp Nephrol; 2002; 10(1):19-25. PubMed ID: 11803201
[TBL] [Abstract][Full Text] [Related]
19. Renal Effects of Sulodexide in Type 2 Diabetic Patients without Nephrotic Range Proteinuria.
Yongwatana K; Supasyndh O; Satirapoj B
J Diabetes Res; 2020; 2020():2984680. PubMed ID: 32851094
[TBL] [Abstract][Full Text] [Related]
20. Melatonin attenuates hypertension-induced renal injury partially through inhibiting oxidative stress in rats.
Qiao YF; Guo WJ; Li L; Shao S; Qiao X; Shao JJ; Zhang Q; Li RS; Wang LH
Mol Med Rep; 2016 Jan; 13(1):21-6. PubMed ID: 26531807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
